234 related articles for article (PubMed ID: 7630741)
1. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy.
Becker W; Schrell U; Buchfelder M; Hensen J; Wendler J; Gramatzki M; Wolf F
Nuklearmedizin; 1995 Jun; 34(3):100-3. PubMed ID: 7630741
[TBL] [Abstract][Full Text] [Related]
2. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
3. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.
Lincke T; Singer J; Kluge R; Sabri O; Paschke R
Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
[TBL] [Abstract][Full Text] [Related]
5. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
6. [Accumulation of radioactivity in the lung after 111In-octreotide scintigraphy].
Schleicher UM; Cremerius U; Schubert H
Rofo; 1998 Apr; 168(4):404-6. PubMed ID: 9589108
[No Abstract] [Full Text] [Related]
7. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
8. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
9. 111In-octreotide in the evaluation of autoimmune thyroid diseases.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Del Vecchio E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):127-30. PubMed ID: 9002770
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.
Krassas GE; Dumas A; Pontikides N; Kaltsas T
Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496
[TBL] [Abstract][Full Text] [Related]
12. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
13. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
[TBL] [Abstract][Full Text] [Related]
14. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
15. [Radionuclide diagnosis of thyroid diseases].
Slavnov VN
Vrach Delo; 1984 Sep; (9):54-9. PubMed ID: 6209859
[No Abstract] [Full Text] [Related]
16. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
17. The relevance of somatostatin receptors in thyroid neoplasia.
Ahlman H; Tisell LE; Wängberg B; Fjälling M; Forssell-Aronsson E; Kölby L; Nilsson O
Yale J Biol Med; 1997; 70(5-6):523-33. PubMed ID: 9825479
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy in non-medullary thyroid cancer.
Postema PT; De Herder WW; Reubi JC; Oei HY; Kwekkeboom DJ; Bruining HJ; Bonjer J; van Toor H; Hennemann G; Krenning EP
Digestion; 1996; 57 Suppl 1():36-7. PubMed ID: 8813465
[TBL] [Abstract][Full Text] [Related]
19. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
Adrian HJ; Dörr U; Bach D; Bihl H
Horm Metab Res Suppl; 1993; 27():18-23. PubMed ID: 8330868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]